Lupin Ltd (LUPIN) is currently trading at 2,220.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Lupin is a global, innovation-led pharmaceutical company that develops and markets branded and generic formulations, biosimilars, injectables, inhalation products and APIs across 100+ countries, with particular strength in cardiovascular, diabetology, respiratory and anti-TB. The company combines a large India commercial footprint with a growing regulated-market presence in the United States and other developed markets. Q3 FY26 was a company record: consolidated sales of INR 71,005 million (↑26% YoY), EBITDA of INR 22,095 million (↑62% YoY) with a 31.1% margin, and net income of INR 11,756 million (↑38% YoY); Lupin highlighted broad-based regional growth led by a USD 350 million quarter in the US, driven by Tolvaptan, Mirabegron and new product momentum. Lupin is pivoting R&D and commercial strategy toward complex generics, injectables and biosimilars: the company announced US FDA approval for pegfilgrastim (Armlupeg™), has a rich pipeline of inhalation, injectables and biosimilars targeting multiple launches through FY28–FY31, and plans 10–15 ANDA filings in FY26 while targeting 100+ new product launches across platforms by FY31. India remains a core growth engine with the Rx business growing 10.9% in Q3 FY26 and chronic therapies now ~67% of the portfolio; Lupin is building a semaglutide-focused division, expects to be a day-one participant in obesity/GLP-1 launches, and projects sustained outperformance of the domestic market through product launches and salesforce expansion. Lupin is strengthening its ESG credentials while scaling complex product capability: the company achieved a 91/100 S&P Global ESG rating, CDP double A, SBTi approval for GHG targets and is advancing water recycling and zero-waste initiatives, underlining a simultaneous focus on sustainability, regulatory compliance improvements and quality remediation across manufacturing sites.

Over the past 52 weeks, Lupin Ltd has traded between a low of ₹1,881.80 and a high of ₹2,530.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Lupin Ltd has a market capitalization of approximately 1,01,734.24. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Lupin Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.40 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,01,734.24 Cr, Lupin Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Lupin Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Lupin Ltd is 18.40. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations was ₹8,276.89 crore and consolidated PAT was ₹1,416.98 crore for the quarter ended June 30, 2026.

Lupin received final USFDA approval for its ANDA for Diazepam Injection, USP, 10 mg/2 mL (5 mg/mL), packaged as single-dose prefilled syringes.

Lupin’s board is scheduled to meet on August 6, 2026, to review and approve the Q1 FY27 financial results for the quarter ended June 30, 2026.

Lupin’s board is scheduled to meet on August 6, 2026, to review and approve Q1 FY27 results. The exact release time was not officially specified in advance.